Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
Nordisk
since
auto-detected in 451 stories
41 days ago
42 days ago
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.
43 days ago
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Novo Nordisk said Thursday that the rampant growth of the U.S.' compounded drug industry was hurting Wegovy sales, and warned it was considering legal action against companies it believes to be viola…
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Novo Nordisk said Thursday that the rampant growth of the U.S.' compounded drug industry was hurting Wegovy sales, and warned it was considering legal action against companies it believes to be viola…
46 days ago
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.
59 days ago
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.
60 days ago
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
|← first ← previous page 3 of 5 next → last →|